Hystar, a prominent player in the proton exchange membrane (PEM) electrolyser space, is poised to catalyze the global transition to green hydrogen with an array of ambitious expansion plans.
The company’s vision includes the establishment of a colossal 4GW fully automated facility in Norway by 2025, the inauguration of a new manufacturing site in North America in 2024, and the creation of a multi-gigawatt factory on the horizon by 2027.
At present, Hystar boasts a stack production capacity for upcoming electrolyser deployments, capable of delivering 50MW annually at its existing location. However, these figures are set to soar as the company embarks on constructing the monumental 4GW factory in Høvik, Norway, with groundbreaking scheduled for 2024 and full operational capacity expected by 2026.
Hystar’s expansion plans are not confined to European shores. The company is actively engaged in discussions with key stakeholders in the United States and Canada to establish its inaugural North American gigafactory. In this promising market, Hystar envisions commercial operations that could outpace its European counterparts within a decade.
He also underscored the significance of opening headquarters in North America alongside a gigafactory, marking a pivotal milestone in the company’s journey towards global hydrogen leadership.
Hystar is not merely confined to expansion plans; it has a roster of imminent deliveries that underscore its commitment to advancing green hydrogen technologies. Among these deliveries is a 1MW system slated for its HyPilot project in Norway, set to launch in collaboration with industry heavyweights such as Yara and Equinor in Q4 2023.
Moreover, Hystar is gearing up to supply Polish energy firm Polenergia with a 5MW electrolyser in Q3 2024 for its H2HubNS project in Nowa Sarzyna, Poland, demonstrating its international reach and commitment to green hydrogen.
Hystar’s ambitious growth plans have been bolstered by its successful Series B funding round in January 2023, which raised an impressive $26 million. This infusion of capital is instrumental in facilitating the company’s transition to full-scale commercial production.
